| Date Filed | Type | Description |
| 02/14/2020 |
SC 13G/A
| Redmile Group, LLC reports a 0% stake in Nightstar Therapeutics plc |
| 02/04/2020 |
SC 13G/A
| Woodford Investment Management LLP reports a 0% stake in Nightstar Therapeutics plc |
| 06/17/2019 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 06/12/2019 |
SC 13D/A
| New Enterprise Associates 15, L.P. has filed a Schedule 13D for Nightstar Therapeutics plc |
| 06/10/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 06/10/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 06/10/2019 |
8-K
| Quarterly results |
| 06/07/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 05/29/2019 |
8-K
| Other Events, Financial Statements and Exhibits |
| 05/09/2019 |
10-Q
| Quarterly Report for the period ended March 31, 2019 |
| 05/08/2019 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits |
| 04/30/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/30/2019 |
10-K/A
| Annual Report for the period ended December 31, 2018 [amend] |
| 04/26/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2019 |
SC 13D
| Polygon Global Partners LLP reports a 8% stake in Nightstar Therapeutics plc |
| 04/16/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/10/2019 |
SC 13G/A
| WELLINGTON MANAGEMENT GROUP LLP reports a 0% stake in Nightstar Therapeutics plc |
| 04/09/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/09/2019 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 03/18/2019 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/18/2019 |
10-K
| Annual Report for the period ended December 31, 2018 |
| 03/18/2019 |
PREM14A
| Form PREM14A - Preliminary proxy statements relating to merger or acquisition: |
| 03/14/2019 |
SC 13D
| BIOGEN INC. reports a 61.6% stake in Nightstar Therapeutics plc |
| 03/14/2019 |
SC 13G/A
| Syncona Portfolio Ltd reports a 39% stake in Nightstar Therapeutics plc |
| 03/13/2019 |
SC 13D/A
| New Enterprise Associates 15, L.P. reports a 19.9% stake in Nightstar Therapeutics plc |
| 03/05/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/04/2019 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
| 03/04/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 02/14/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2019 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/14/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2019 |
SC 13G/A
| Syncona Portfolio Ltd reports a 39% stake in Nightstar Therapeutics plc |
| 02/12/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/20/2018 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
|